![](https://news.europawire.eu/wp-content/uploads/2022/09/basilea-HQ-144x144.jpg)
(IN BRIEF) Basilea Pharmaceutica Ltd (SIX: BSLN), a biopharmaceutical company specializing in severe bacterial and fungal infection treatments, has announced an asset purchase agreement with Spexis AG (SIX: SPEX) for a preclinical antibiotics program aimed at combating Gram-negative bacteria, including … Read the full press release